IDiyas

For the Inventor, By the Inventor

Beijing, China

Shaojing Hu

USPTO Granted Patents = 14 


 

Average Co-Inventor Count = 5.7

ph-index = 3

Forward Citations = 24(Granted Patents)


Company Filing History:

goldMedal11 out of 19 
 
Betta Pharmaceuticals Co., Ltd.
 patents
silverMedal3 out of 15 
 
Jacobio Pharmaceuticals Co., Ltd.
 patents

Years Active: 2015-2024

where 'Filed Patents' based on already Granted Patents

14 patents (USPTO):
1. 12103929 - Tricyclic compounds (2024-10-01),
2. 11466005 - Tricyclic compounds (2022-10-11),
3. 10988466 - Heterocyclic derivatives useful as SHP2 inhibitors (2021-04-27),
4. 10577364 - Crystalline form of fused pyridine derivative's maleate and uses thereof (2020-03-03),
5. 10059688 - Protein tyrosine kinase modulators and methods of use (2018-08-28),
6. 9783524 - Protein tyrosine kinase modulators and methods of use (2017-10-10),
7. 9688687 - Polymorphic forms of icotinib phosphate and uses thereof (2017-06-27),
8. 9617257 - Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors (2017-04-11),
9. 9611272 - Polymorphic forms of icotinib and uses thereof (2017-04-04),
10. 9505774 - Polymorphic forms of icotinib maleate and uses thereof (2016-11-29),
11. 9487570 - Glucagon like peptide analogs, composition, and method of use (2016-11-08),
12. 9242991 - Substituted fused heterocycles as c-Met tyrosine kinase inhibitors (2016-01-26),
13. 9085588 - Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof (2015-07-21),
14. 8951959 - Glucagon-like peptide-1 analogues and uses thereof (2015-02-10),

Title: Innovator Shaojing Hu: Pioneering Advances in Tricyclic Compounds

Introduction: Shaojing Hu, an accomplished inventor based in Beijing, China, has made significant contributions to the field of medicinal chemistry. With a portfolio of 14 patents, he is recognized for his innovative work on compounds that hold the potential to treat various diseases.

Latest Patents: Among his latest inventions, Shaojing Hu has disclosed tricyclic compounds as bromodomain and extra-terminal (BET) inhibitors. These compounds are represented by specific structures and have been thoroughly researched for their synthesis and therapeutic uses. More particularly, these fused heterocyclic derivatives serve as competitive inhibitors of BET bromodomains, a critical target in treating several health conditions. The methodologies for synthesizing these compounds are also elaborated, highlighting their importance in mitigating specific diseases where BET inhibition is beneficial.

Career Highlights: Shaojing Hu has built a promising career in pharmaceutical research, having worked with leading companies in the biotech industry, including Betta Pharmaceuticals and Jacobio Pharmaceuticals. His expertise and innovation have led to the development of novel therapeutic approaches, paving the way for advancements in drug discovery.

Collaborations: Throughout his career, Shaojing has collaborated with notable professionals such as Wei Long and Yinxiang Wang. These partnerships have fostered a productive research environment that has significantly contributed to the advancement of their shared goals in medicinal chemistry.

Conclusion: Shaojing Hu's contributions to the field of tricyclic compounds and BET inhibitors underscore his role as a leading inventor in the pharmaceutical industry. With a keen focus on creating therapeutic solutions, he continues to advance the boundaries of medical science, making strides that offer hope for numerous patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…